Schwab M, Roedel M, Anwar M A, Müller T, Schubert H, Buchwalder L F, Walter B, Nathalielsz W
Department of Neurology, Institutes of Laboratory Animal Sciences and Pathophysiology, Friedrich Schiller University, Jena, Germany.
J Physiol. 2000 Nov 1;528(Pt 3):619-32. doi: 10.1111/j.1469-7793.2000.00619.x.
Glucocorticoid administration to women at risk of preterm delivery to accelerate fetal lung maturation has become standard practice. Antenatal glucocorticoids decrease the incidence of intraventricular haemorrhage as well as accelerating fetal lung maturation. Little is known regarding side effects on fetal cerebral function. Cortisol and synthetic glucocorticoids such as betamethasone increase fetal blood pressure and femoral vascular resistance in sheep. We determined the effects of antenatal glucocorticoid administration on cerebral blood flow (CBF) in fetal sheep. Vehicle (n = 8) or betamethasone (n = 8) was infused over 48 h via the jugular vein of chronically instrumented fetal sheep at 128 days gestation (term 146 days). The betamethasone infusion rate was that previously shown to produce fetal plasma betamethasone concentrations similar to human umbilical vein concentrations during antenatal glucocorticoid therapy. Regional CBF was measured in 10 brain regions, using coloured microspheres, before and 24 and 48 h after onset of treatment, and during hypercapnic challenges performed before and 48 h after onset of betamethasone exposure. Betamethasone exposure decreased CBF in all brain regions measured except the hippocampus after 24 h of infusion (P < 0.05). The CBF decrease was most pronounced in the thalamus and hindbrain (45-50% decrease) and least pronounced in the cortical regions (35-40% decrease). It was mediated by an increase in cerebral vascular resistance (CVR, P < 0.05) and led to a decrease in oxygen delivery to subcortical and hindbrain structures of 30-40%, to 8.6 +/- 1.1 ml x (100 g)(-1) x min(-1), and 40-45 %, to 11.0 +/- 1.6 ml x 100 g(-1) x min(-1), respectively (P < 0.05). After 48 h of betamethasone treatment, the reduction in CBF was diminished to about 25-30 %, but was still significant in comparison to vehicle-treated fetuses in all brain regions except three of the five measured cortical regions (P < 0.05). CVR and oxygen delivery were unchanged in comparison to values at 24 h of treatment. The CBF increase in response to hypercapnia was diminished (P < 0.05). These observations demonstrate for the first time that glucocorticoids exert major vasoconstrictor effects on fetal CBF. This mechanism may protect the fetus against intraventricular haemorrhage both at rest and when the fetus is challenged. Betamethasone exposure decreased the hypercapnia-induced increase in CBF (P < 0.05) due to decreased cerebral vasodilatation (P < 0.05).
给有早产风险的女性使用糖皮质激素以加速胎儿肺成熟已成为标准做法。产前使用糖皮质激素可降低脑室内出血的发生率,并加速胎儿肺成熟。关于其对胎儿脑功能的副作用知之甚少。皮质醇和合成糖皮质激素(如倍他米松)可增加绵羊胎儿的血压和股血管阻力。我们确定了产前使用糖皮质激素对绵羊胎儿脑血流量(CBF)的影响。在妊娠128天(足月为146天)时,通过长期植入仪器的绵羊胎儿的颈静脉,在48小时内输注载体(n = 8)或倍他米松(n = 8)。倍他米松的输注速率是先前显示的能使胎儿血浆倍他米松浓度类似于产前糖皮质激素治疗期间人脐静脉浓度的速率。在治疗开始前、治疗开始后24小时和48小时,以及在倍他米松暴露开始前和暴露后48小时进行高碳酸血症激发试验期间,使用彩色微球在10个脑区测量局部脑血流量。输注倍他米松24小时后,除海马体外,所测量的所有脑区的脑血流量均降低(P < 0.05)。脑血流量的降低在丘脑和后脑最为明显(降低45 - 50%),在皮质区域最不明显(降低35 - 40%)。这是由脑血管阻力(CVR,P < 0.如果他在那里,我肯定会见到他。05)增加介导的,导致输送到皮质下和后脑结构的氧气减少30 - 40%,降至8.6±1.1 ml x (100 g)(-1) x min(-1),以及40 - 45%,降至11.0±1.6 ml x 100 g(-1) x min(-1),分别(P < 0.05)。倍他米松治疗48小时后,脑血流量的降低减少至约25 - 30%,但与载体处理的胎儿相比,在除五个测量皮质区域中的三个区域外的所有脑区仍具有统计学意义(P < 0.05)。与治疗24小时时的值相比,脑血管阻力和氧气输送没有变化。对高碳酸血症的脑血流量增加反应减弱(P < 0.05)。这些观察结果首次表明,糖皮质激素对胎儿脑血流量具有主要的血管收缩作用。这种机制可能在胎儿休息和受到刺激时保护胎儿免受脑室内出血。由于脑血管扩张减少(P < 0.05),倍他米松暴露降低了高碳酸血症诱导的脑血流量增加(P < 0.05)。